<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Effective therapy of myelodysplatic syndromes and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> originating from <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> has remained an unresolved problem </plain></SENT>
<SENT sid="1" pm="."><plain>Advanced age of the patients and persistent <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> make the treatment difficult </plain></SENT>
<SENT sid="2" pm="."><plain>Despite large number of therapeutic options none of them is satisfactory </plain></SENT>
<SENT sid="3" pm="."><plain>Recently palliative treatment with low-dose melphalan has been reported to have certain activity </plain></SENT>
<SENT sid="4" pm="."><plain>The aim of the study was to evaluate the efficacy of low-dose melphalan in high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty three patients were eligible for the study: 8 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and 15 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of them received oral melphalan in a daily dose of 2 mg </plain></SENT>
<SENT sid="7" pm="."><plain>Median total dose of the drug was 120 mg (40-840 mg) </plain></SENT>
<SENT sid="8" pm="."><plain>Ten patients responded to the therapy </plain></SENT>
<SENT sid="9" pm="."><plain>We observed complete remission (CR) in 4, partial remission (PR) in 3 and stabilization of the disease in 3 patients </plain></SENT>
<SENT sid="10" pm="."><plain>Thirteen patients did not respond to the therapy </plain></SENT>
<SENT sid="11" pm="."><plain>The survival time of the patients from the day of diagnosis and from the beginning of the treatment with melphalan was longer in patients responding to the therapy (median 15 and 10 months, respectively) than in non-responders (4.5 and 4 months, p=0.003 and p=0.008, respectively) </plain></SENT>
<SENT sid="12" pm="."><plain>Low-dose melphalan shows significant activity in high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> with acceptable toxicity </plain></SENT>
</text></document>